Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen
We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen. Subjects were 10 836 adults who initiated first-line cART (two nucleosi...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2017-12, Vol.72 (12), p.3425-3434 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3434 |
|---|---|
| container_issue | 12 |
| container_start_page | 3425 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 72 |
| creator | Raffi, François Hanf, Matthieu Ferry, Tristan Khatchatourian, Lydie Joly, Véronique Pugliese, Pascal Katlama, Christine Robineau, Olivier Chirouze, Catherine Jacomet, Christine Delobel, Pierre Poizot-Martin, Isabelle Ravaux, Isabelle Duvivier, Claudine Gagneux-Brunon, Amandine Rey, David Reynes, Jacques May, Thierry Bani-Sadr, Firouzé Hoen, Bruno Morrier, Marine Cabie, André Allavena, Clotilde |
| description | We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen.
Subjects were 10 836 adults who initiated first-line cART (two nucleoside or nucleotide reverse transcriptase inhibitors + efavirenz, a ritonavir-boosted protease inhibitor or an integrase inhibitor) from 1 January 2007 to 31 December 2014. Cox proportional hazards models with multiple adjustment and propensity score matching were used to investigate the effect of baseline HIV-1 RNA and time to virological suppression on the occurrence of virological rebound.
During 411 436 patient-months of follow-up, risk of virological rebound was higher in patients with baseline HIV-1 RNA ≥100 000 copies/mL versus 6 months versus 100 000 copies/mL was associated with virological rebound for ritonavir-boosted protease inhibitors but not for efavirenz or integrase inhibitors. Time to virological suppression >6 months was strongly associated with virological rebound for all regimens.
In HIV-1-infected patients starting cART, risk of virological rebound was lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. These data, from a very large observational cohort, in addition to the more rapid initial virological suppression obtained with integrase inhibitors, reinforce the positioning of this class as the preferred one for first-line therapy. |
| doi_str_mv | 10.1093/jac/dkx300 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_inserm_01686859v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1945218541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-464b0138e8a0be2db4d3297692450499c540b987bd7dd6b489fc5576a25fece13</originalsourceid><addsrcrecordid>eNpNkctu1DAUhi0EotPChgdAXiLUtMfxJfZyVJXOSCOQELC1fMvgksTBTip4iL4zmU5bIR3pLM73_2fxIfSOwAUBRS9vjbv0v_5QgBdoRZiAqgZFXqIVUOBVwzg9Qael3AKA4EK-Rie1VII0RK3Q_bYfjZtwarE1JXRxCHjsTOkN3mx_VAR__bzGZvB4in3AU8J3Macu7aMzHS7zOOZQSkwDXub_Uw42zUvMOJeyj8P-kG1jLlP18MMMU8xhymkJPeD7pX94g161pivh7eM-Q98_XX-72lS7Lzfbq_WuclTAVDHBLBAqgzRgQ-0t87RWjVA148CUcpyBVbKxvvFeWCZV6zhvhKl5G1wg9AydH3t_mk6POfYm_9XJRL1Z73QcSsi9BiKkkFzdHfAPR3zM6fccyqT7WFzoOjOENBdNFOM1kZwd0I9H1OVUSg7tcz0BfbClF1v6aGuB3z_2zrYP_hl90kP_Aa9Kkl4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1945218541</pqid></control><display><type>article</type><title>Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Raffi, François ; Hanf, Matthieu ; Ferry, Tristan ; Khatchatourian, Lydie ; Joly, Véronique ; Pugliese, Pascal ; Katlama, Christine ; Robineau, Olivier ; Chirouze, Catherine ; Jacomet, Christine ; Delobel, Pierre ; Poizot-Martin, Isabelle ; Ravaux, Isabelle ; Duvivier, Claudine ; Gagneux-Brunon, Amandine ; Rey, David ; Reynes, Jacques ; May, Thierry ; Bani-Sadr, Firouzé ; Hoen, Bruno ; Morrier, Marine ; Cabie, André ; Allavena, Clotilde</creator><creatorcontrib>Raffi, François ; Hanf, Matthieu ; Ferry, Tristan ; Khatchatourian, Lydie ; Joly, Véronique ; Pugliese, Pascal ; Katlama, Christine ; Robineau, Olivier ; Chirouze, Catherine ; Jacomet, Christine ; Delobel, Pierre ; Poizot-Martin, Isabelle ; Ravaux, Isabelle ; Duvivier, Claudine ; Gagneux-Brunon, Amandine ; Rey, David ; Reynes, Jacques ; May, Thierry ; Bani-Sadr, Firouzé ; Hoen, Bruno ; Morrier, Marine ; Cabie, André ; Allavena, Clotilde ; Dat’AIDS Study Group</creatorcontrib><description>We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen.
Subjects were 10 836 adults who initiated first-line cART (two nucleoside or nucleotide reverse transcriptase inhibitors + efavirenz, a ritonavir-boosted protease inhibitor or an integrase inhibitor) from 1 January 2007 to 31 December 2014. Cox proportional hazards models with multiple adjustment and propensity score matching were used to investigate the effect of baseline HIV-1 RNA and time to virological suppression on the occurrence of virological rebound.
During 411 436 patient-months of follow-up, risk of virological rebound was higher in patients with baseline HIV-1 RNA ≥100 000 copies/mL versus <100 000 copies/mL, in those achieving virological suppression in > 6 months versus <6 months, and lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. Baseline HIV-1 RNA >100 000 copies/mL was associated with virological rebound for ritonavir-boosted protease inhibitors but not for efavirenz or integrase inhibitors. Time to virological suppression >6 months was strongly associated with virological rebound for all regimens.
In HIV-1-infected patients starting cART, risk of virological rebound was lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. These data, from a very large observational cohort, in addition to the more rapid initial virological suppression obtained with integrase inhibitors, reinforce the positioning of this class as the preferred one for first-line therapy.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkx300</identifier><identifier>PMID: 28961719</identifier><language>eng</language><publisher>England: Oxford University Press (OUP)</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-HIV Agents - administration & dosage ; Antiretroviral Therapy, Highly Active - methods ; Female ; Follow-Up Studies ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-1 - isolation & purification ; Humans ; Life Sciences ; Male ; Middle Aged ; Plasma - virology ; Prospective Studies ; Recurrence ; RNA, Viral - blood ; Santé publique et épidémiologie ; Sustained Virologic Response ; Time Factors ; Viral Load ; Young Adult</subject><ispartof>Journal of antimicrobial chemotherapy, 2017-12, Vol.72 (12), p.3425-3434</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-464b0138e8a0be2db4d3297692450499c540b987bd7dd6b489fc5576a25fece13</citedby><cites>FETCH-LOGICAL-c360t-464b0138e8a0be2db4d3297692450499c540b987bd7dd6b489fc5576a25fece13</cites><orcidid>0000-0002-6150-2376 ; 0000-0003-3070-3017 ; 0000-0002-5093-4800 ; 0000-0002-5676-5411 ; 0000-0001-8268-866X ; 0000-0003-0117-3061 ; 0000-0003-3082-7001</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28961719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-01686859$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Raffi, François</creatorcontrib><creatorcontrib>Hanf, Matthieu</creatorcontrib><creatorcontrib>Ferry, Tristan</creatorcontrib><creatorcontrib>Khatchatourian, Lydie</creatorcontrib><creatorcontrib>Joly, Véronique</creatorcontrib><creatorcontrib>Pugliese, Pascal</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>Robineau, Olivier</creatorcontrib><creatorcontrib>Chirouze, Catherine</creatorcontrib><creatorcontrib>Jacomet, Christine</creatorcontrib><creatorcontrib>Delobel, Pierre</creatorcontrib><creatorcontrib>Poizot-Martin, Isabelle</creatorcontrib><creatorcontrib>Ravaux, Isabelle</creatorcontrib><creatorcontrib>Duvivier, Claudine</creatorcontrib><creatorcontrib>Gagneux-Brunon, Amandine</creatorcontrib><creatorcontrib>Rey, David</creatorcontrib><creatorcontrib>Reynes, Jacques</creatorcontrib><creatorcontrib>May, Thierry</creatorcontrib><creatorcontrib>Bani-Sadr, Firouzé</creatorcontrib><creatorcontrib>Hoen, Bruno</creatorcontrib><creatorcontrib>Morrier, Marine</creatorcontrib><creatorcontrib>Cabie, André</creatorcontrib><creatorcontrib>Allavena, Clotilde</creatorcontrib><creatorcontrib>Dat’AIDS Study Group</creatorcontrib><title>Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen.
Subjects were 10 836 adults who initiated first-line cART (two nucleoside or nucleotide reverse transcriptase inhibitors + efavirenz, a ritonavir-boosted protease inhibitor or an integrase inhibitor) from 1 January 2007 to 31 December 2014. Cox proportional hazards models with multiple adjustment and propensity score matching were used to investigate the effect of baseline HIV-1 RNA and time to virological suppression on the occurrence of virological rebound.
During 411 436 patient-months of follow-up, risk of virological rebound was higher in patients with baseline HIV-1 RNA ≥100 000 copies/mL versus <100 000 copies/mL, in those achieving virological suppression in > 6 months versus <6 months, and lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. Baseline HIV-1 RNA >100 000 copies/mL was associated with virological rebound for ritonavir-boosted protease inhibitors but not for efavirenz or integrase inhibitors. Time to virological suppression >6 months was strongly associated with virological rebound for all regimens.
In HIV-1-infected patients starting cART, risk of virological rebound was lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. These data, from a very large observational cohort, in addition to the more rapid initial virological suppression obtained with integrase inhibitors, reinforce the positioning of this class as the preferred one for first-line therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - isolation & purification</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Plasma - virology</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>RNA, Viral - blood</subject><subject>Santé publique et épidémiologie</subject><subject>Sustained Virologic Response</subject><subject>Time Factors</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkctu1DAUhi0EotPChgdAXiLUtMfxJfZyVJXOSCOQELC1fMvgksTBTip4iL4zmU5bIR3pLM73_2fxIfSOwAUBRS9vjbv0v_5QgBdoRZiAqgZFXqIVUOBVwzg9Qael3AKA4EK-Rie1VII0RK3Q_bYfjZtwarE1JXRxCHjsTOkN3mx_VAR__bzGZvB4in3AU8J3Macu7aMzHS7zOOZQSkwDXub_Uw42zUvMOJeyj8P-kG1jLlP18MMMU8xhymkJPeD7pX94g161pivh7eM-Q98_XX-72lS7Lzfbq_WuclTAVDHBLBAqgzRgQ-0t87RWjVA148CUcpyBVbKxvvFeWCZV6zhvhKl5G1wg9AydH3t_mk6POfYm_9XJRL1Z73QcSsi9BiKkkFzdHfAPR3zM6fccyqT7WFzoOjOENBdNFOM1kZwd0I9H1OVUSg7tcz0BfbClF1v6aGuB3z_2zrYP_hl90kP_Aa9Kkl4</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Raffi, François</creator><creator>Hanf, Matthieu</creator><creator>Ferry, Tristan</creator><creator>Khatchatourian, Lydie</creator><creator>Joly, Véronique</creator><creator>Pugliese, Pascal</creator><creator>Katlama, Christine</creator><creator>Robineau, Olivier</creator><creator>Chirouze, Catherine</creator><creator>Jacomet, Christine</creator><creator>Delobel, Pierre</creator><creator>Poizot-Martin, Isabelle</creator><creator>Ravaux, Isabelle</creator><creator>Duvivier, Claudine</creator><creator>Gagneux-Brunon, Amandine</creator><creator>Rey, David</creator><creator>Reynes, Jacques</creator><creator>May, Thierry</creator><creator>Bani-Sadr, Firouzé</creator><creator>Hoen, Bruno</creator><creator>Morrier, Marine</creator><creator>Cabie, André</creator><creator>Allavena, Clotilde</creator><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-3070-3017</orcidid><orcidid>https://orcid.org/0000-0002-5093-4800</orcidid><orcidid>https://orcid.org/0000-0002-5676-5411</orcidid><orcidid>https://orcid.org/0000-0001-8268-866X</orcidid><orcidid>https://orcid.org/0000-0003-0117-3061</orcidid><orcidid>https://orcid.org/0000-0003-3082-7001</orcidid></search><sort><creationdate>20171201</creationdate><title>Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen</title><author>Raffi, François ; Hanf, Matthieu ; Ferry, Tristan ; Khatchatourian, Lydie ; Joly, Véronique ; Pugliese, Pascal ; Katlama, Christine ; Robineau, Olivier ; Chirouze, Catherine ; Jacomet, Christine ; Delobel, Pierre ; Poizot-Martin, Isabelle ; Ravaux, Isabelle ; Duvivier, Claudine ; Gagneux-Brunon, Amandine ; Rey, David ; Reynes, Jacques ; May, Thierry ; Bani-Sadr, Firouzé ; Hoen, Bruno ; Morrier, Marine ; Cabie, André ; Allavena, Clotilde</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-464b0138e8a0be2db4d3297692450499c540b987bd7dd6b489fc5576a25fece13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - isolation & purification</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Plasma - virology</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>RNA, Viral - blood</topic><topic>Santé publique et épidémiologie</topic><topic>Sustained Virologic Response</topic><topic>Time Factors</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raffi, François</creatorcontrib><creatorcontrib>Hanf, Matthieu</creatorcontrib><creatorcontrib>Ferry, Tristan</creatorcontrib><creatorcontrib>Khatchatourian, Lydie</creatorcontrib><creatorcontrib>Joly, Véronique</creatorcontrib><creatorcontrib>Pugliese, Pascal</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>Robineau, Olivier</creatorcontrib><creatorcontrib>Chirouze, Catherine</creatorcontrib><creatorcontrib>Jacomet, Christine</creatorcontrib><creatorcontrib>Delobel, Pierre</creatorcontrib><creatorcontrib>Poizot-Martin, Isabelle</creatorcontrib><creatorcontrib>Ravaux, Isabelle</creatorcontrib><creatorcontrib>Duvivier, Claudine</creatorcontrib><creatorcontrib>Gagneux-Brunon, Amandine</creatorcontrib><creatorcontrib>Rey, David</creatorcontrib><creatorcontrib>Reynes, Jacques</creatorcontrib><creatorcontrib>May, Thierry</creatorcontrib><creatorcontrib>Bani-Sadr, Firouzé</creatorcontrib><creatorcontrib>Hoen, Bruno</creatorcontrib><creatorcontrib>Morrier, Marine</creatorcontrib><creatorcontrib>Cabie, André</creatorcontrib><creatorcontrib>Allavena, Clotilde</creatorcontrib><creatorcontrib>Dat’AIDS Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raffi, François</au><au>Hanf, Matthieu</au><au>Ferry, Tristan</au><au>Khatchatourian, Lydie</au><au>Joly, Véronique</au><au>Pugliese, Pascal</au><au>Katlama, Christine</au><au>Robineau, Olivier</au><au>Chirouze, Catherine</au><au>Jacomet, Christine</au><au>Delobel, Pierre</au><au>Poizot-Martin, Isabelle</au><au>Ravaux, Isabelle</au><au>Duvivier, Claudine</au><au>Gagneux-Brunon, Amandine</au><au>Rey, David</au><au>Reynes, Jacques</au><au>May, Thierry</au><au>Bani-Sadr, Firouzé</au><au>Hoen, Bruno</au><au>Morrier, Marine</au><au>Cabie, André</au><au>Allavena, Clotilde</au><aucorp>Dat’AIDS Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>72</volume><issue>12</issue><spage>3425</spage><epage>3434</epage><pages>3425-3434</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen.
Subjects were 10 836 adults who initiated first-line cART (two nucleoside or nucleotide reverse transcriptase inhibitors + efavirenz, a ritonavir-boosted protease inhibitor or an integrase inhibitor) from 1 January 2007 to 31 December 2014. Cox proportional hazards models with multiple adjustment and propensity score matching were used to investigate the effect of baseline HIV-1 RNA and time to virological suppression on the occurrence of virological rebound.
During 411 436 patient-months of follow-up, risk of virological rebound was higher in patients with baseline HIV-1 RNA ≥100 000 copies/mL versus <100 000 copies/mL, in those achieving virological suppression in > 6 months versus <6 months, and lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. Baseline HIV-1 RNA >100 000 copies/mL was associated with virological rebound for ritonavir-boosted protease inhibitors but not for efavirenz or integrase inhibitors. Time to virological suppression >6 months was strongly associated with virological rebound for all regimens.
In HIV-1-infected patients starting cART, risk of virological rebound was lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. These data, from a very large observational cohort, in addition to the more rapid initial virological suppression obtained with integrase inhibitors, reinforce the positioning of this class as the preferred one for first-line therapy.</abstract><cop>England</cop><pub>Oxford University Press (OUP)</pub><pmid>28961719</pmid><doi>10.1093/jac/dkx300</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-3070-3017</orcidid><orcidid>https://orcid.org/0000-0002-5093-4800</orcidid><orcidid>https://orcid.org/0000-0002-5676-5411</orcidid><orcidid>https://orcid.org/0000-0001-8268-866X</orcidid><orcidid>https://orcid.org/0000-0003-0117-3061</orcidid><orcidid>https://orcid.org/0000-0003-3082-7001</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2017-12, Vol.72 (12), p.3425-3434 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_inserm_01686859v1 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Adolescent Adult Aged Aged, 80 and over Anti-HIV Agents - administration & dosage Antiretroviral Therapy, Highly Active - methods Female Follow-Up Studies HIV Infections - drug therapy HIV Infections - virology HIV-1 - isolation & purification Humans Life Sciences Male Middle Aged Plasma - virology Prospective Studies Recurrence RNA, Viral - blood Santé publique et épidémiologie Sustained Virologic Response Time Factors Viral Load Young Adult |
| title | Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T11%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20baseline%20plasma%20HIV-1%20RNA%20and%20time%20to%20virological%20suppression%20on%20virological%20rebound%20according%20to%20first-line%20antiretroviral%20regimen&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Raffi,%20Fran%C3%A7ois&rft.aucorp=Dat%E2%80%99AIDS%20Study%20Group&rft.date=2017-12-01&rft.volume=72&rft.issue=12&rft.spage=3425&rft.epage=3434&rft.pages=3425-3434&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkx300&rft_dat=%3Cproquest_hal_p%3E1945218541%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1945218541&rft_id=info:pmid/28961719&rfr_iscdi=true |